{
  "docId": "019de076-9103-7399-8bed-9b1b1a8b182a",
  "docSlug": "93c36ca1f8977b3a70b566ce0ab54138",
  "documentTitle": "argenx SE | Investor Conference Presentation Deck | 27 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 27,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a two-stage framework to present clinical data and patient outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9103-7399-8bed-9b1b1a8b182a/11",
  "deckHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a",
  "deckJsonHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a.json",
  "deckAnchorHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.38,
        "y": 0.48
      },
      "kind": "chart",
      "text": "Kaplan-Meier curve showing probability of no relapse",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9035c3f-78b0-48ec-9302-5146748621a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.75,
        "y": 0.46
      },
      "kind": "metric",
      "text": "99%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01a75bc5-e059-4fa2-a949-ee659be5e116",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.08,
        "x": 0.25,
        "y": 0.25
      },
      "kind": "metric",
      "text": "67%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46f80f73-74f6-4ce1-a154-badaeb5722d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.08,
        "x": 0.25,
        "y": 0.55
      },
      "kind": "metric",
      "text": "61%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78c84402-823c-4249-a9a6-25a32d0d5c88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.75,
        "y": 0.33
      },
      "kind": "metric",
      "text": "99%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80c443ca-8673-4606-a732-56c5017a3735",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Stage B: SET NEW STANDARD FOR HOW CIDP TRIALS ARE RUN",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30e5c02b-fbf4-4ffb-aaf2-17b710625f1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Response rate demonstrates IgG autoantibodies play significant role in underlying CIDP biology",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62ab4708-0cdd-4283-9745-ca09bf275de4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Stage A: ESTABLISHED CIDP AS IgG MEDIATED",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb589cc7-eaf7-4e7f-9f8f-dcf99ffcbf3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.25,
        "y": 0.92
      },
      "kind": "paragraph",
      "text": "sBLA submitted with priority review voucher",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd2010b9-e8af-4167-b602-8b74634baa25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "VYVGART Has Potential to Transform CIDP",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd43541e-be1d-4ff2-8d69-195a6865bf34",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "10300344-3ff1-4b97-95a5-8662d641a2aa",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Rising Success",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "Highlighting commercial execution and market opportunities",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 5,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "f381209b-40fa-4c32-8920-66d6dea883b8",
      "evidence": "Discussion of innovation horizons and market opportunities",
      "position": 0,
      "objective": "Why now is the time for argenx SE's innovation",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}